Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer

Completed · Phase 1

Conditions studied: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific

In brief

Phase I trial to study the effectiveness of combining interleukin-12 and interferon alfa in treating patients who have residual, recurrent, or metastatic malignant melanoma or other advanced cancer that has not responded to standard therapy. Interleukin-12 may stimulate a person's white blood cells to kill cancer cells. Interferon alfa may interfere with the growth of the cancer cells. Combining interleukin-12 with interferon alfa may kill more cancer cells.

Key facts

Study ID

NCT00003451

Run by

National Cancer Institute (NCI)

People needed

40

Starts

1998-08-01

Last updated by the study team

2013-02-01

Who can join

Age: 13 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Arthur G. James Cancer Hospital - Ohio State University — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.